Enliven Historical Balance Sheet

ELVN Stock

21.51 0.93 4.52%

Trend analysis of Enliven Therapeutics balance sheet accounts such as Other Current Liabilities of 7.3 M or Total Current Liabilities of 9 M provides information on Enliven Therapeutics' total assets, liabilities, and equity, which is the actual value of Enliven Therapeutics to its prevalent stockholders. By breaking down trends over time using Enliven Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Enliven Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enliven Therapeutics is a good buy for the upcoming year.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

About Enliven Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Enliven Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Enliven Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Enliven Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Enliven currently owns. An asset can also be divided into two categories, current and non-current.

Enliven Therapeutics Balance Sheet Chart

At this time, Enliven Therapeutics' Other Stockholder Equity is very stable compared to the past year. As of the 27th of March 2025, Total Current Assets is likely to grow to about 334 M, while Short and Long Term Debt Total is likely to drop about 253.1 K.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of Enliven Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Enliven Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Enliven Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Enliven Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Enliven Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Enliven Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.At this time, Enliven Therapeutics' Other Stockholder Equity is very stable compared to the past year. As of the 27th of March 2025, Total Current Assets is likely to grow to about 334 M, while Short and Long Term Debt Total is likely to drop about 253.1 K.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	323K	335K	301.5K	253.1K
Total Assets	83.3M	271.9M	325.8M	342.0M

Short Long Term Debt Total Total Assets

Enliven Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Short Term Investments	Other Liab	Net Tangible Assets	Current Deferred Revenue	Capital Lease Obligations	Net Invested Capital
Total Assets		-0.49	0.78	0.8	0.91	-0.86	-0.95	0.31	0.79	1.0	0.95	0.07	0.68	0.94	0.2	1.0	0.92	0.42	0.69	0.81	0.95	-0.77	-0.77	0.79	-0.05	0.92
Short Long Term Debt Total	-0.49		-0.32	-0.39	-0.21	0.63	0.4	-0.6	-0.62	-0.49	-0.31	-0.54	-0.23	-0.29	-0.53	-0.49	-0.25	-0.34	-0.14	-0.17	-0.32	0.25	0.46	-0.38	-0.09	-0.26
Other Current Liab	0.78	-0.32		0.99	0.76	-0.59	-0.76	0.17	0.6	0.77	0.77	-0.07	0.97	0.76	0.06	0.78	0.78	0.5	0.78	0.66	0.76	-0.31	-0.73	0.84	0.41	0.76
Total Current Liabilities	0.8	-0.39	0.99		0.73	-0.64	-0.78	0.3	0.65	0.79	0.76	0.02	0.95	0.75	0.16	0.8	0.76	0.59	0.8	0.68	0.74	-0.33	-0.8	0.89	0.45	0.74
Total Stockholder Equity	0.91	-0.21	0.76	0.73		-0.6	-0.93	-0.02	0.52	0.91	0.98	-0.33	0.68	0.99	-0.21	0.91	0.99	0.17	0.7	0.88	0.99	-0.8	-0.57	0.65	-0.22	1.0
Net Debt	-0.86	0.63	-0.59	-0.64	-0.6		0.69	-0.49	-0.98	-0.87	-0.67	-0.54	-0.47	-0.65	-0.64	-0.86	-0.6	-0.51	-0.43	-0.47	-0.69	0.52	0.78	-0.72	-0.09	-0.61
Retained Earnings	-0.95	0.4	-0.76	-0.78	-0.93	0.69		-0.33	-0.61	-0.94	-0.98	0.11	-0.64	-0.97	-0.01	-0.94	-0.95	-0.39	-0.83	-0.94	-0.94	0.82	0.74	-0.81	0.12	-0.94
Accounts Payable	0.31	-0.6	0.17	0.3	-0.02	-0.49	-0.33		0.48	0.3	0.16	0.69	0.04	0.12	0.72	0.3	0.06	0.77	0.38	0.28	0.07	-0.2	-0.7	0.57	0.33	0.01
Cash	0.79	-0.62	0.6	0.65	0.52	-0.98	-0.61	0.48		0.8	0.58	0.6	0.47	0.56	0.69	0.79	0.51	0.49	0.42	0.37	0.6	-0.37	-0.75	0.72	0.17	0.52
Cash And Short Term Investments	1.0	-0.49	0.77	0.79	0.91	-0.87	-0.94	0.3	0.8		0.95	0.07	0.66	0.94	0.2	1.0	0.92	0.4	0.68	0.8	0.95	-0.77	-0.77	0.78	-0.07	0.92
Common Stock Shares Outstanding	0.95	-0.31	0.77	0.76	0.98	-0.67	-0.98	0.16	0.58	0.95		-0.21	0.67	1.0	-0.09	0.95	0.99	0.3	0.77	0.92	0.99	-0.83	-0.69	0.74	-0.17	0.99
Non Current Liabilities Total	0.07	-0.54	-0.07	0.02	-0.33	-0.54	0.11	0.69	0.6	0.07	-0.21		-0.16	-0.25	0.98	0.06	-0.31	0.53	-0.15	-0.29	-0.23	0.19	-0.39	0.24	0.4	-0.33
Other Current Assets	0.68	-0.23	0.97	0.95	0.68	-0.47	-0.64	0.04	0.47	0.66	0.67	-0.16		0.67	-0.02	0.68	0.71	0.47	0.67	0.56	0.67	-0.21	-0.62	0.72	0.49	0.69
Other Stockholder Equity	0.94	-0.29	0.76	0.75	0.99	-0.65	-0.97	0.12	0.56	0.94	1.0	-0.25	0.67		-0.13	0.94	1.0	0.26	0.75	0.92	0.99	-0.84	-0.65	0.71	-0.2	0.99
Total Liab	0.2	-0.53	0.06	0.16	-0.21	-0.64	-0.01	0.72	0.69	0.2	-0.09	0.98	-0.02	-0.13		0.19	-0.19	0.61	-0.03	-0.17	-0.11	0.11	-0.51	0.36	0.44	-0.2
Total Current Assets	1.0	-0.49	0.78	0.8	0.91	-0.86	-0.94	0.3	0.79	1.0	0.95	0.06	0.68	0.94	0.19		0.92	0.41	0.68	0.81	0.95	-0.77	-0.77	0.78	-0.06	0.92
Common Stock	0.92	-0.25	0.78	0.76	0.99	-0.6	-0.95	0.06	0.51	0.92	0.99	-0.31	0.71	1.0	-0.19	0.92		0.23	0.75	0.91	0.99	-0.81	-0.62	0.69	-0.18	1.0
Property Plant And Equipment Net	0.42	-0.34	0.5	0.59	0.17	-0.51	-0.39	0.77	0.49	0.4	0.3	0.53	0.47	0.26	0.61	0.41	0.23		0.51	0.39	0.21	-0.16	-0.84	0.72	0.71	0.17
Non Current Assets Total	0.69	-0.14	0.78	0.8	0.7	-0.43	-0.83	0.38	0.42	0.68	0.77	-0.15	0.67	0.75	-0.03	0.68	0.75	0.51		0.88	0.68	-0.48	-0.73	0.9	0.18	0.7
Non Currrent Assets Other	0.81	-0.17	0.66	0.68	0.88	-0.47	-0.94	0.28	0.37	0.8	0.92	-0.29	0.56	0.92	-0.17	0.81	0.91	0.39	0.88		0.86	-0.83	-0.67	0.75	-0.14	0.88
Short Term Investments	0.95	-0.32	0.76	0.74	0.99	-0.69	-0.94	0.07	0.6	0.95	0.99	-0.23	0.67	0.99	-0.11	0.95	0.99	0.21	0.68	0.86		-0.81	-0.63	0.67	-0.22	0.99
Other Liab	-0.77	0.25	-0.31	-0.33	-0.8	0.52	0.82	-0.2	-0.37	-0.77	-0.83	0.19	-0.21	-0.84	0.11	-0.77	-0.81	-0.16	-0.48	-0.83	-0.81		0.47	-0.42	0.51	-0.81
Net Tangible Assets	-0.77	0.46	-0.73	-0.8	-0.57	0.78	0.74	-0.7	-0.75	-0.77	-0.69	-0.39	-0.62	-0.65	-0.51	-0.77	-0.62	-0.84	-0.73	-0.67	-0.63	0.47		-0.91	-0.39	-0.57
Current Deferred Revenue	0.79	-0.38	0.84	0.89	0.65	-0.72	-0.81	0.57	0.72	0.78	0.74	0.24	0.72	0.71	0.36	0.78	0.69	0.72	0.9	0.75	0.67	-0.42	-0.91		0.38	0.65
Capital Lease Obligations	-0.05	-0.09	0.41	0.45	-0.22	-0.09	0.12	0.33	0.17	-0.07	-0.17	0.4	0.49	-0.2	0.44	-0.06	-0.18	0.71	0.18	-0.14	-0.22	0.51	-0.39	0.38		-0.22
Net Invested Capital	0.92	-0.26	0.76	0.74	1.0	-0.61	-0.94	0.01	0.52	0.92	0.99	-0.33	0.69	0.99	-0.2	0.92	1.0	0.17	0.7	0.88	0.99	-0.81	-0.57	0.65	-0.22

Click cells to compare fundamentals

Enliven Therapeutics Account Relationship Matchups

Enliven Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	131.0M	113.3M	83.3M	271.9M	325.8M	342.0M
Other Current Liab	565K	3.1M	6.0M	25.0M	14.6M	7.3M
Total Current Liabilities	1.5M	5.8M	9.7M	25.9M	15.9M	9.0M
Total Stockholder Equity	(20.3M)	(42.9M)	(76.8M)	245.9M	309.8M	325.3M
Net Debt	(130.3M)	(109.9M)	(75.2M)	(99.8M)	(124.1M)	(117.9M)
Retained Earnings	(20.5M)	(45.2M)	(82.9M)	(154.4M)	(243.5M)	(231.3M)
Accounts Payable	808K	2.5M	3.4M	532K	1.3M	1.6M
Cash	130.4M	110.0M	75.5M	100.1M	124.1M	77.3M
Cash And Short Term Investments	130.4M	110.0M	75.5M	253.1M	313.4M	329.1M
Common Stock Shares Outstanding	3.5M	7.8M	6.2M	35.5M	47.1M	49.4M
Liabilities And Stockholders Equity	131.0M	113.3M	83.3M	271.9M	325.8M	342.0M
Non Current Liabilities Total	184.0K	149.8M	150.5M	150.4M	67K	0.0
Other Current Assets	222K	646K	2.2M	13.0M	4.7M	3.2M
Other Stockholder Equity	157K	2.3M	6.2M	400.2M	553.2M	580.9M
Total Liab	151.3M	156.2M	160.1M	26.0M	15.9M	15.1M
Total Current Assets	130.6M	110.7M	77.8M	266.2M	318.1M	334.0M
Property Plant And Equipment Net	416K	954K	1.5M	1.1M	458K	888.8K
Non Current Assets Total	416K	2.7M	5.5M	5.7M	7.6M	4.5M
Non Currrent Assets Other	(88K)	1.5M	4.0M	4.7M	7.2M	7.5M
Short Term Investments	40.5M	42.0M	0.0	153.0M	189.3M	198.8M
Accumulated Other Comprehensive Income	4K	(16K)	(149.7K)	141K	55K	57.8K

When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:

How To Invest In Enliven

Details

Is Enliven Stock a good investment?

Details

What is Enliven Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.82)

Return On Assets

(0.22)

Return On Equity

(0.32)

The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enliven Historical Balance Sheet

About Enliven Balance Sheet Analysis

Enliven Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Enliven Therapeutics balance sheet Correlations

Enliven Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enliven Therapeutics balance sheet Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 1.0	Common Stock Shares Outstanding
Common Stock	+ 1.0	Other Stockholder Equity

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Total Assets
Net Invested Capital	- 0.94	Retained Earnings